Johnson & Johnson's (JNJ) therapy candidate TAR-200 received breakthrough therapy designation from the FDA for the treatment of high risk bladder cancer.
https://seekingalpha.com/news/4043187-jj-gets-fda-breakthrough-status-for-tar-200-in-bladder-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.